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The pathogenesis of glaucoma, a common neurodegenerative disease, involves an immunologic
component. Changes in the natural autoantibody proﬁle of glaucoma patients were detected, showing
not only up-regulated but also down-regulated immunoreactivities. In recent studies we were able to
demonstrate that the antibody changes have a large inﬂuence on protein proﬁles of neuroretinal cells.
Furthermore we could demonstrate neuroprotective potential of one of the down-regulated antibodies
(g-synuclein antibody). Anti-GFAP antibody is another antibody found down-regulated in glaucoma
patients. Since GFAP expression is intensiﬁed in glaucomatous retina, the aim of this study was to detect
the effect of GFAP antibodies on neuroretinal cells. This is realized with a viability-test as well as pro-
teomic analysis of cells incubated with GFAP antibodies. Furthermore, possible interaction partners of the
GFAP antibody in neuroretinal cells were identiﬁed by western blot, mass spectrometry and indirect
immunoﬂuorescence staining. We found that the GFAP antibody is able to protect cells from oxidative
stress, which is due to changed protein expressions of the actin cytoskeleton. Furthermore we detected a
cross-reaction of the antibody to endoplasmic reticulum resident protein 57 on the cell membrane,
which seems to lead to a changed signaling in the cells triggering the protective effects.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Glial ﬁbrillary acidic protein (GFAP) is a cytoskeletal type III
intermediate ﬁlament and was ﬁrst isolated frommultiple sclerosis
plaques (1). Intermediate ﬁlament maintain cell stability as well as
cell shape. GFAP additionally plays a role in the modulation of cell
motility, proliferation, vesicle trafﬁcking and interaction between
astrocytes and neurons (2) and is a main component in astrocytes
of the central nervous system. Following acute injury of the brain,
but also progressive central nervous system degeneration,phate buffered saline; endo-
ﬁbrillary acidic protein, GFAP.
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d/4.0/).astrocytes are activated resulting in reactive gliosis. Activated as-
trocytes express enhanced GFAP levels (3) and exist in many
neurodegenerative disorders such as Alzheimer's (4, 5) and Par-
kinson's disease (6). Furthermore, activated glial cells expressing
increased GFAP levels were detected in glaucoma animal models
(7) and human glaucomatous donor eyes (8). Studies also demon-
strated reactive astrocytes in the optic nerve head of monkey
glaucoma models (9). Glaucoma is a common neurodegenerative
disease and one of the leading courses for blindness worldwide
(10). It comprises a heterogeneous group of eye diseases, deﬁned by
a progressive loss of retinal ganglion cells, optic nerve degeneration
and resulting visual ﬁelds defects (11). Although so frequent, the
reason for its development is still unknown. Amajor risk factor is an
elevated intraocular eye pressure, but the fact that 30% of glaucoma
patients fail to demonstrate this symptom (12) reveals, that other
pathogenesis factors are involved, such as immunological compo-
nents. Complex analysis of sera derived from numerous glaucoma
patients showed up-as well as down-regulated autoantibodies
against alpha-foldrin (up-regulated) or aB-Crystallin and Vimentin
(down-regulated) and additionally complex changes in thenese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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Furthermore, antibody reactions in the aqueous humour of glau-
coma patients against antigens such as aB-Crystallin (down-regu-
lated), Vimentin (down-regulated) and Hsp 70 (up-regulated) (15)
were detected.
After incubating neuroretinal cells (R28) with glaucoma serum,
we found signiﬁcantly changed protein expression proﬁles of the
cells in comparison to cells incubated with healthy serum (16).
These changes mainly involved cell regulatory pathway proteins.
We also found that antibodies in the serum of glaucoma patients
had the largest signiﬁcant impact on the detected protein expres-
sion changes (16). These results emphasize the hypothesis that
changes of autoantibodies participate in glaucoma disease.
Recently we showed that g-synuclein antibody, down-regulated in
glaucoma patients, has a protective effect on stressed neuroretinal
cells (retinal ganglion cell line 5). This effect can be traced back to
anti-apoptotic altered protein expressions in the mitochondrial
apoptosis pathway (17). After demonstrating protective effects of g-
synuclein antibody the aim of this study was to analyze whether
other antibodies, also down-regulated in glaucoma, possess similar
properties, or if the cells possible react contradictory.
2. Material and methods
2.1. Reagents
20, 70-dichlorodihydroﬂuorescein-diacetate from SigmaeAldrich
(St. Louis, MO). Polyclonal antibody tomyoglobin, rabbit anti-sheep
IgG-H&L (FITC), mouse monoclonal antibody to endoplasmic re-
ticulum resident protein 57 (ERP57), rabbit polyclonal secondary
antibody tomouse IgG-H&L (TRITC), chicken polyclonal antibody to
GFAP and rabbit polyclonal secondary antibody to chicken IgY-H&L
(FITC) were fromAbcam, (Cambridge, UK). BCA Pierce Protein Assay
kit was purchased from Fisher scientiﬁc (Waltham, MA.). Goat anti-
chicken IgY-Horseradish peroxidase was from Santa Cruz (Califor-
nia, U.S.A.).
2.2. Cell culture
Retinal ganglion cell line 5 provided by Dr. Neeraj Agarwal, are
mouse cells transformed with a j2E1A virus (18) and represent a
neuronal precursor cell line (19). Studies show neuron like char-
acteristics and a speciﬁc expression of neuronal proteins (20). The
cells were grown in 75 cm2 culture ﬂasks in Dulbecco's modiﬁed
eagle medium supplemented with 10% fetal calf serum, 100 U/ml
penicillin, 100 U/ml streptomycin and 4% L-alanyl-L-glutamin and
cultivated in a humidiﬁed incubator at 37 C, and 5% CO2.
2.2.1. Cell treatment with GFAP antibodies and different stress
factors
Retinal ganglion cell line 5 cells were seeded in 24 well plates at
a density of 45000 and grown overnight. After preincubation with
different concentrations of polyclonal anti-GFAP antibodies [0.005
and 20 mg/ml (n ¼ 4) and 0.1, 0.5, 1, 5, 10 mg/ml (n ¼ 6)], the cells
were incubated with 50 mMH2O2 for 1 h to induce oxidative stress.
In order to detect the speciﬁcity of the results the experiments were
also performedwith different concentrations of rabbit polyclonal to
myoglobin antibodies and either stressed with 50 mM H2O2.
2.2.2. Cell viability test
Cell viability was assessed with crystal violet staining. The cells
were ﬁxed with 3% paraformaldehyde (15 min) and rinsed with
phosphate buffered saline (PBS). Subsequently the cells were
stained with 0.1% crystal violet solution according to the protocol
(17). The absorption was expressed as percentage of the controlcells, which were only treated with H2O2. An unpaired student's t-
test was used to compare the data obtained and was calculated
with Statistica (StatSoft, U.S.A.). A p-value <0.05 is described as
signiﬁcant and p < 0.01 as highly signiﬁcant.
2.2.3. Reactive oxygen species-test
To quantify reactive oxygen species we used 20, 70
dichlorodihydroﬂuorescein-diacetate. Intracellular esterase and
reactive oxygen species convert non-ﬂuorescence stain 20, 70
dichlorodihydroﬂuorescein-diacetate to ﬂuorescent stain dichlor-
oﬂuorescein. Cells were loaded with 10 mM 20, 70
dichlorodihydroﬂuorescein-diacetate in the incubation chamber
according to the protocol (17) The absorption was expressed as a
percentage of the control cells only treated with 50 mM H2O2.
Reactive oxygen species-levels were normalized by measuring the
viability of the cells in the same well. An unpaired student t-test
was used to compare the data obtained (Statistica).
2.3. Immunocytochemical staining
Retinal ganglion cell line 5 were grown in m-slide IV (Ibidi
GmbH, Munich, Germany) overnight and subsequently washed
with PBS. The cells were ﬁxed with 3% paraformaldehyde (15min)
and incubated with 0.25% Triton-X-100 in PBS (12 min). After 3
wash steps (PBS), the cells were treated with 1% bovine serum al-
bumin (20 min). Then the cells were incubated with 2 mg/ml
chicken polyclonal anti-GFAP antibodies overnight, gently washed
3 times with PBS and incubated with rabbit polyclonal secondary
antibody to chicken IgY-H&L (FITC) (1.5 h). After washing (PBS), the
cells were visualized with a Leica ﬂuorescence microscope using
Lucia G/F software. To investigate the antibody staining in living
cells, the cells were treated with 15 mg/ml polyclonal anti-GFAP
antibodies and washed with PBS. The cell membrane was visual-
ized using wheat germ agglutinin and the cells were handled and
visualized as described above. Immunocytochemical staining was
also performed to visualize ERP57 and GFAP in non-permeabilized
ﬁxed cells. Cells were ﬁxed as described above and incubated with
5 mg monoclonal anti-ERP57 antibody and 2 mg/ml polyclonal anti-
GFAP antibody overnight. After washing, the cells were incubated
with rabbit polyclonal secondary antibody to mouse IgG-H&L
(TRITC) and rabbit polyclonal secondary antibody to chicken IgY-
H&L (FITC).
2.4. Mass spectrometric analyses
2.4.1. Cell lysate preparation
For proteomic analysis, cells were grown in 60  15 mm cell
culture dishes overnight and subsequently incubated with 1 mg/ml
polyclonal anti-GFAP antibodies for 3 h. Control cells were incu-
bated without antibodies. After washing with PBS they were de-
tached from the cell culture dish with cell dissociation solution and
lysed by freezing at 80 C, adding 0.1% w/v Dodecyl-D-b- Malto-
side and treatment in an ultrasonic bath for 1 min. After centrifu-
gation, the supernatant was used for protein concentration
determination by BCA Pierce Protein Assay kit.
2.4.2. SDS PAGE separation and in-gel digestion
Protein separation was performed via denaturing gel electro-
phoresis. Each lane was cut into 17 pieces, incubated with aceto-
nitril and ammonium bicarbonate and dried in a concentrator. Then
the pieces were tryptically digested overnight, based on a modiﬁed
protocol of Shevchenkov (21) (0.7 mg Trypsin in 80% HPLC H2O, 10%
acetonitril, 10% ammonium bicarbonate). The supernatant was
collected and remaining proteins were dissolved with extraction
buffer (38% HPLC H2O, 0.2% formic acid, 60% acetonitril) for 30 min.
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ﬁed with 0.1% triﬂuoroacetic. C-18 ZipTips were used to purify the
samples according to the manufacture protocol. The samples were
then dried and frozen at 20 till further analysis.
2.4.3. LC-ESI/MS for protein identiﬁcation
Analysis of peptides was performed with a capillary LC-ESI-MS
system consisting of a BioBasic C-18 precolumn
(30 mm  0.5 mm, Thermo Scientiﬁc) and a BioBasic C18 analytical
column (150 mm  0.5 mm, Thermo Scientiﬁc). The system was
protected by an A 316 0.5 mm online precolumn ﬁlter (Upchurch
Scientiﬁc, Washington, U.S.A.). As solvent delivery system, a Rheos
Allegro HPLC Pump (Thermo Scientiﬁc) was used. The pump ﬂow
rate was 200 ml/min and reduced to a column ﬂow of 10 ml/min by
use of anM472 graduatedmicro-split valve (Upchurch, Scientiﬁc).
Using running buffer A (98% H2O, 1.94% acetonitril, 0.06%methanol,
0.05% triﬂuoroacetic) and B (95% acetonitril, 3 %methanol, 2% H2O
and 0.05% triﬂuoroacetic), a linear gradient of 80 min was per-
formed (0e47 min: 0e100 %B, 47e49 min: 100% B, 49e58: 100 %e
0 % B, 58e80min: 0 %B). Equilibration gradients of 30 minwere run
between samples by injecting 80% acetonitril to prevent sample-to-
sample carry over. Mass spectra were obtained using an LTQ
OrbitrapXL and were recorded in the “proﬁle” mode to allow
quantiﬁcation in MaxQuant (Max Planck Institute of Biochemistry,
Martinsried, Germany) with settings as described in previous
studies (17).
2.4.4. Data processing
The mass spectra were used for protein identiﬁcation and
quantiﬁcation with Maxquant with a ﬁxed modiﬁcation Carbami-
domethylation. The tolerance in mass precision for MS/MS was
20 ppm and 0.5 Da. The protein and peptide false discovery rate
were set of 0.01 and the minimum peptide length was 6 amino
acids. The evaluation was implemented with Ingenuity Pathway
Analysis Software to investigate biological networks and pathways.
We included only proteins with a 2-fold changed expression in
GFAP antibody treated cells to the analysis.
2.4.5. Identiﬁcation of GFAP antibody binding partners
100 mg cell lysate was dissolved in 125 ml sample solution (2% w/
v chaps, 8 M Urea, 2 M Thiourea, 0.8% v/v Bromphenol blue solu-
tion, 0.8% v/v Proteinase inhibitor cocktail, 1% v/v immobiline pH-
gradient buffer 3e10 non-linear). After incubation (30 min, 4 C)
the cell lysates were applied to Immobiline dry-strips pH 3e10Fig. 1. Reactive oxygen species-level and viability of GFAP antibody treated and stressed c
ﬂuorescein-diacetate. The viability test was performed with crystal violet. (*¼p < 0.05; **
centrations of GFAP antibodies for 3 h and additionally stressed with 50 mM H2O2 for 1 h. S
were preincubated with 0.5e5 mg/ml GFAP antibodies in comparison to stressed cells. B: In
were preincubated with 0.1e1 mg/ml GFAP antibodies and additionally stressed with H2O2.non-linear (7 cm). After isoelectric focusing, the gel strips were
equilibrated (6 M urea, 75 mM TriseHCl pH 8.8, 29.3% v/v glycerol,
2% w/v SDS, 0.002% v/v bromphenol blue) containing 2.5% w/v
Dithiothreitol (12 min) and then in equilibrating buffer containing
3.2% w/v Iodacetamid (12 min) whilst gentle shaking. The second
dimension (SDS-Page) was carried out using a 12% acrylamide gel.
Gels were either stained with colloidal blue staining kit or electro-
blotted to nitrocellulose for western blotting. Blots were blocked in
4% non-fat-dry milk (1 h) and incubated with anti-GFAP antibody
overnight. After washing, the blot was incubated with secondary
antibody coupled with horseradish peroxidase (2 h). The spots
identiﬁed by western blot, were excised in the corresponding gel
and digested as described above. The peptides were deposited
directly on a 386MTP polished steel Maldi target (Bruker Daltonics,
Bremen, Germany) and the matrix (20 mg alpha-cyano-4-
hxdroxycinnamic acid, 60% acetonitril, 40% H2O, 0.1% triﬂuoro-
acetic) was applied, after drying the samples. 3 spots with 2 ml
peptide calibration standard mixed with 18 ml matrix were applied.
The applied spots weremeasured with an Ultraﬂex II Maldi-Time of
ﬂight/Time of ﬂight (TOF) MS (Bruker Daltonics). The identiﬁed
interaction partner of the GFAP antibody was used to create an
antigen microarray. The identiﬁed antigen was spotted on a nitro-
cellulose slide using an array-spotter (Scienion, Germany). The
microarray slides was blocked with 5% bovine serum albumin in
0.5% Tween-PBS (1 h), washed three times with 0.5% Tween-PBS,
subsequently incubated with anti-GFAP antibody overnight and
incubatedwith anti-IgY secondary antibody coupledwith FITC (2 h)
after 3 wash steps. The spots were visualized with Leica ﬂuores-
cence microscope using Lucia G/F software.
3. Results
3.1. Effect of GFAP antibodies on stressed retinal ganglion cell 5
The effects of GFAP antibodies were determined by viability and
reactive oxygen species-tests. We detected signiﬁcant increased
cell viability of up to 9%, when preincubating the cells with 0.1
(p < 0.05), 0.5 (p < 0.05), 1 (p < 0.01) mg/ml GFAP antibodies and
additionally stressing themwith H2O2 in comparison to the control
cells only treated with H2O2 (Fig. 1). The concentrations ranging
from 0.5 to 5 mg/ml GFAP antibodies also showed signiﬁcantly
decreased reactive oxygen species-levels of up to 9% (p < 0.05) in
H2O2 stressed cells (Fig. 1). No signiﬁcant effect was found, when
the cells were incubated with lower concentrations of theells. Reactive oxygen species-production was measured using 20 , 70-dichlorodihydro-
p < 0.01). A: Retinal ganglion cell line 5 cells were preincubated with different con-
igniﬁcant decreased reactive oxygen species-production was measured, when the cells
creased high signiﬁcant and signiﬁcant cell viability was demonstrated after the cells
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show a signiﬁcant decreased viability of 6% and a highly signiﬁ-
cant increased reactive oxygen species-level of 10% in comparison
to untreated cells.
To validate the speciﬁcity of the protective effect of GFAP anti-
bodies, the experiment was also performed with anti-myoglobin
antibodies as control antibodies. We could indicate no signiﬁcant
change of viability when preincubating cells with different con-
centrations of myoglobin antibodies and additionally stressing with
H2O2 in comparison to untreated stressed cells (data not shown).3.2. Mass spectrometric analysis
To investigate GFAP antibodies effects on the protein expression
of retinal ganglion cell line 5, proteomic analyses of cells after
preincubation with GFAP antibodies in comparison to untreated
cells were performed. Overall we identiﬁed 486 proteins and 102
signiﬁcant protein alterations with intensity differences of 2 fold
increase or decrease (Supplement File I). These changed proteins
were analyzed with Ingenuity Pathway Analysis and classiﬁed into
31 signiﬁcant canonical pathways. Among these pathways we
found the actin cytoskeleton signaling pathway to be of particular
interest. We indicated 7 associated proteins differently expressed,
namely actin beta, proﬁlin1, Talin 1, Vinculin, Spectrin alpha (up-
regulated) and actin regulated protein 2, Coﬁlin 1 (down-regu-
lated), all involved in regulating the actin cytoskeleton organiza-
tion. (Fig. 2).
3.3. GFAP antibody binding partner in retinal ganglion cell line 5
To determine GFAP expression and GFAP antibody binding in-
direct immunoﬂuorescence staining was performed. Permeabilized
ﬁxed cells showed cytoplasmatic staining in the area of the nucleus
(Supplementary Fig. 1) whereas the antibody bound to the cell
membrane in non-permeabilized cells (Fig. 4B). We could not
detect antibody internalization or binding in living cells pre-
incubated with GFAP antibodies. Western blot and Maldi analysis
were used to identify possible interaction partners. Western blot
analysis visualized two GFAP antibody binding sites. One spot was
identiﬁed at a molecular weight of 49 kDa, which correlates with
the molecular weight of GFAP and the second spot was seen at a
molecular weight of 56 kDa. Maldi analysis identiﬁed the second
spot as ERP57, which was conﬁrmed in a microarray approachFig. 2. Regulation of actin cytoskeleton associated proteins. Cells were preincubated with 1 m
performed via capillary LC-ESI-MS system. A: Regulation of actin cytoskeleton proteins. Qu
parison to untreated control cells. The dashed line highlights the relevant regulated proteins
constructed by means of biocarta (www.biocarta.com). The red colored proteins demonstratshowing GFAP antibody binding to the antigen ERP57 (Fig. 3B). The
expression of ERP57 on the cell membrane and also around the
nucleus of non-permeabilized and permeabilized cells was shown
in immunocytochemical staining. Double staining of ERP57 and
GFAP of non permeabilized cells showed the same staining pattern
on the cell membrane, thus we assume that GFAP antibody binds to
ERP57 on the cell membrane of the cells (Fig. 4).4. Discussion
These studies show a dose response effect of the GFAP antibody,
with protective effects in the range from 0.1 to 5 mg/ml, lower
concentrations do not show any effect, higher concentrations show
negative effects on the cells. In contrast to the long lasted opinion
that autoantibodies are auto-aggressive like in Myasthenia gravis
(22, 23), previous studies could also show the protective potential
of autoantibodies. In Alzheimers' disease autoantibodies against
Ab, which are also found down-regulated in the patients, convey a
protective effect by inhibiting oligomerization of Ab peptides (24,
25). In addition to the protective effects of the GFAP antibody on
neuroretinal cells, our group was also able to show the protective
potential of g-synuclein antibodies, down-regulated in glaucoma
patients (17). Proteomic analysis showed that the actin cytoskel-
eton pathway is effected by the GFAP antibody. The actin cyto-
skeleton, which is the main microﬁlament in axons, consists of
dynamic assembly and disassembly ﬁlaments and is essential for a
lot of biological functions such as mechanic cell stabilization, cell
motility, vesicle trafﬁcking, endocytosis, intracellular organization
and apoptosis (26). The actin dynamic is regulated by different actin
regulated proteins like Proﬁlin, Coﬁlin and actin regulated protein
2/3, which were down-regulated in GFAP antibody treated cells and
Vinculin, Talin, alpha Spectrin, up-regulated in GFAP antibody
treated cells. Next to mechanic cell stability, studies could show,
that actin dynamics are also involved in apoptosis regulation.
Cytochalasin d, which prevents polymerization of f-actin, can
induce caspase 3 mediated apoptosis in t-lymphocytes (27)
whereas Phalloidin, a f-actin stabilization drug, prevents nuclear
fragmentation by apoptosis in cisplatin treated kidney cells (28).
Cells are dependent on actin dynamics and changes can affect
apoptosis signaling pathways demonstrated by the fact that actin
and actin regulated proteins participate in the mitochondrial
apoptosis pathway (26). Direct inﬂuence of actin and actin regu-
lated proteins on the mitochondrial apoptosis pathway has alsog/ml GFAP antibodies and subsequently lyzed, tryptically digested. Protein analyses was
antiﬁcations were realized with MaxQuant. The fold changes were calculated in com-
(>2fold changed expression). B: Overview of changed proteins of the actin cytoskeleton
e that the protein is up-regulated and the green colored that they are down-regulated.
Fig. 3. Identiﬁcation of GFAP antibody interaction partners via western blot and microarray. A: 2-D gel electrophoresis with cell lysate was performed. The proteins were electro
blotted to nitrocellulose and incubated with anti-GFAP antibody overnight. The identiﬁed spots by western blot were excised in the corresponding gel, digested and identiﬁed with
Ultraﬂex II Maldi-TOF/TOF MS. Spot 1 was identiﬁed as ERP57 and spot 2 was identiﬁed as GFAP. B: Antigen microarray show the binding of GFAP antibody to ERP57.
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dependent anion channel in the fungus Neurospora crassa (29).
Voltage dependent anion channel is located on the outer mito-
chondrial membrane and participates in energy balance regulation
as well as the release of pro-apoptotic factors such as cytochrome c.
Actin regulated proteins e.g. Coﬁlin, which is altered in GFAP
antibody treated cells, also is involved in mitochondrial apoptosis.
Coﬁlin promotes depolymerization of actin and is involved in G-
actin recycling. After induction of apoptosis, dephosphorylated
Coﬁlin translocates from the cytosol to the mitochondria and can
induce cytochrome c release (30). Over-expression of Gelsolin,
which belongs also to the actin regulated proteins, inhibits
apoptosis in Jurkat cells induced through several mitochondrial
target drugs (31). Gelsolin also has a protective effect on neuronal
cells by preventing the loss of mitochondrial membrane potential
and activation of caspase-3 (32). All these ﬁndings verify the
participation of the actin cytoskeleton and actin regulated proteins
on apoptosis pathways especially on mitochondrial apoptosis.
These studies propose, that the dynamic transformation of the
actin cytoskeleton plays an important role in stress response of
cells. Disorganization of the cytoskeleton could be observed in a
glaucoma rat model with increased intraocular pressure. Control
animals showed a consistent distribution of f-actin in the nerve
fascicle, whereas a diffuse distribution could be observed in ani-
mals with an increased intraocular pressure (33). Mass spectro-
metric analyses are not suitable to detect structural changes such as
polymerziation or depolymerization of the actin cytoskeleton, but
they clearly show changes in the protein expression of actin cyto-
skeleton proteins.
The immunocytochemical staining showed binding of the
antibody in the cytosol located around the nucleus inside the
permeabilized cells and on the membrane of non-permeabilized
cells. We detected the interaction of the antibody with GFAP and
ERP57. The hypothesis, that antibody-antigen binding is mono-
speciﬁc, has changed since many monoclonal antibody were found
to bind to unrelated self and foreign antibodies (34, 35). So-called
polyreactive antibodies are able to bind to different antigens due
to conformational changes in the antigen-binding pocket (35).
These polyreactive natural antibodies are produced by poly-
reactive B-cells as a part of their physiological function (36). Aspostulated by Notkins, polyspeciﬁcity is not exclusive for natural
antibodies, but rather a general property of antibodies (35).
Possibly the GFAP antibodies are polyreactive and able to bind
unrelated antigens such as ERP57. ERP57 is a thiol oxidoreductase
and belongs to the protein disulﬁde isomerase family. All members
of the family are present in the endoplasmatic reticulum and
participate in proper protein folding. They catalyze oxidation,
reduction and isomerization of disulﬁde bonds. There is evidence
that some members of the protein disulﬁde isomerase family have
a different cellular location and the function differs from those
found in the endoplasmic reticulum lumen (37). Whilst the
function of ERP57 in the endoplasmic reticulum is well under-
stood, the physiological function in the nucleus or the cell mem-
brane, is not understood very well. In common with our ﬁndings
protein disulﬁde isomerase has been found on the cell surface of
different cell types such as hepatocytes (38), endothelial cells (39)
and neuroblastoma NG108e15 cells (40). ERP57 possesses an
important role in signal transduction processes from the cell
membrane to the cytoplasm. The involvement of ERP57 in signal
transducer and activator of transcription 3 signaling pathway was
also demonstrated (41). As yet, there is no direct link between
plasma membrane associated ERP57 and actin cytoskeleton
signaling, but studies were able to show the association of ERP57
and actin as well as Vimentin in the nucleus. The permeabilized
cells did not show typical GFAP staining which was not surprising,
considering the cells to be neuronal rather than glial origin. The
protective effect is much more triggered through the binding on
ERP57, localized on the cell membrane.
We hypothesize that GFAP antibody binding on ERP57 of the cell
membrane leads to alterations of the actin cytoskeleton pathway
and therefore leads to a protective effect of H2O2 stressed cells. The
negative effect of high GFAP antibody concentrations could be a
result of a permanent blockage of ERP57. We could detect the GFAP
antibody binding on the cell membrane on ﬁxed cells. In compar-
ison, in living cells preincubated with GFAP antibody, no staining
could be visualized. It is known that ERP57 catalyzes oxidation,
reduction and isomerization of disulﬁde bonds and therefore it
could also remodel disulﬁde bonds of the GFAP antibody. This could
lead to a change of the GFAP antibody epitope preventing the
detection by immunocytochemical staining.
Fig. 4. Binding of GFAP antibody on ERP57 on non permeabilized cells revealed by immunocﬂuorescence. Cells were ﬁxed, blocked and stained with chicken anti-GFAP antibody and
rabbit anti-ERP57 antibody and then stained with a secondary antibody to chicken IgY-H&L conjugated with FITC and a rabbit polyclonal secondary antibody to mouse IgG-H&L
(TRITC). Magniﬁcation 40x. A: Anti-ERP57 (red). B: Anti-GFAP (green). C: Merged ﬂuorescence image. D: Merged ﬂuorescence image with bright light microscopy.
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In summary, immunocytochemical staining as well as Maldi
TOF/TOF and microarray analyses could show, that GFAP anti-
body binds to ERP57 on the cell membrane, and that GFAP
antibody incubation leads to a protective effect on H2O2 stressed
neuroretinal cells. The protective effect could be traced back to
altered proteins of the actin cytoskeleton pathway. These results
show that an antibody not only has to be destructive but also
can have protective effect on cells. This gives initial hints of the
function of down-regulated antibody in the pathogenesis
of glaucoma. We hypothesize that the down-regulation of au-
toantibodies in glaucoma patients results in a loss of protective
regulatory functions, but additional studies have to observe
the detailed function of GFAP antibody in the context of
glaucoma.
We believe that these results show the potential for using pro-
tective autoantibodies to support glaucoma therapy and inhibiting
the loss of retinal ganglion cells, e.g. as personalized therapy.Conﬂicts of interest
None declared.
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